Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,820Revenue $M85.6Net Margin (%)-30.8Z-Score14.1
Enterprise Value $M3,656EPS $-1.9Operating Margin %-24.7F-Score5
P/E(ttm))0Cash Flow Per Share $-2.0Pre-tax Margin (%)-30.8Higher ROA y-yY
Price/Book25.210-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales25.25-y EBITDA Growth Rate %-62.2Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-22.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-64.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M35.9ROI % (ttm)-53.4Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXRon Baron 2014-06-30 Add0.05%$63.61 - $91.01
($75.89)
$ 104.1337%Add 802.88%154,393
PCRXJoel Greenblatt 2014-06-30 Buy 0.01%$63.61 - $91.01
($75.89)
$ 104.1337%New holding, 9486 sh.9,486
PCRXMariko Gordon 2014-06-30 Reduce-0.66%$63.61 - $91.01
($75.89)
$ 104.1337%Reduce -17.39%1,132,552
PCRXMariko Gordon 2014-03-31 Add0.19%$55.83 - $80.43
($67.63)
$ 104.1354%Add 5.13%1,371,042
PCRXRon Baron 2014-03-31 Add$55.83 - $80.43
($67.63)
$ 104.1354%Add 163.28%17,100
PCRXMariko Gordon 2013-12-31 Add2.08%$47.74 - $56.97
($52.53)
$ 104.1398%Add 203.52%1,304,190
PCRXRon Baron 2013-12-31 Buy $47.74 - $56.97
($52.53)
$ 104.1398%New holding, 6495 sh.6,495
PCRXMariko Gordon 2013-09-30 Add0.93%$30.01 - $47.47
($36.37)
$ 104.13186%Add 3812.66%429,688
PCRXMariko Gordon 2013-06-30 Buy 0.02%$25.84 - $30.26
($28.93)
$ 104.13260%New holding, 10982 sh.10,982
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PCRX Joel Greenblatt 2014-06-309,4860.030.01New Buy
PCRX Ron Baron 2014-06-30154,3930.430.06+802.88%
PCRX Mariko Gordon 2014-06-301,132,5523.164.3-17.39%
Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STACK DAVID MPresident, CEO and Chairman 2014-10-15Sell15,000$99.495.29view
HASTINGS PAUL JDirector 2014-10-10Sell2,500$94.8710.41view
LONGENECKER JOHN P PHDDirector 2014-09-29Sell1,000$96.48.66view
Wicki AndreasDirector 2014-08-29Sell21,494$108.11-3.11view
Wicki AndreasDirector 2014-08-27Sell55,813$108.08-3.08view
Wicki AndreasDirector 2014-08-11Sell150,000$101.253.46view
Scibetta James SSVP, CFO 2014-08-08Sell15,000$99.635.14view
PATOU GARYChief Medical Officer 2014-08-07Sell20,000$100.264.48view
STACK DAVID MPresident, CEO and Chairman 2014-07-15Sell15,000$86.7520.75view
PATOU GARYChief Medical Officer 2014-07-14Sell29,700$86.9620.46view

Press Releases about PCRX :

Quarterly/Annual Reports about PCRX:

News about PCRX:

Articles On GuruFocus.com
Mariko Gordon's First Quarter Top Five May 15 2014 
Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
comment on PCRX Mar 15 2013 
Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 


More From Other Websites
Nasdaq stocks posting largest percentage decreases Oct 23 2014
Valeant (VRX) Beats Earnings Estimates in Q3, Shares Gain Oct 23 2014
EQUITY ALERT: Rosen Law Firm Reminds Pacira Pharmaceuticals, Inc. Investors of Important Class... Oct 22 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira... Oct 21 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Pacira... Oct 17 2014
Pacira Pharmaceuticals (PCRX): Strong Industry, Solid Earnings Estimate Revisions Oct 16 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Oct 15 2014
Sucampo/Takeda Amend Collaboration Agreement for Amitiza Oct 15 2014
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and... Oct 15 2014
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and... Oct 15 2014
Pacira (PCRX) Reveals Additional Safety Data on Exparel Oct 14 2014
Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Oct 14 2014
Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral... Oct 13 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000... Oct 10 2014
Vertex Pharmaceuticals (VRTX) Updates on Kalydeco Studies Oct 10 2014
Lightning Round: Hertz, Plug Power & more Oct 08 2014
Bank Of America Sees Significant Manufacturing Capacity Expansions Underway For Pacira... Oct 08 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Oct 07 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Oct 07 2014
Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against... Oct 07 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK